Condition: Metastatic Head and Neck Cancer · Recurrent Head and Neck Cancer · HPV Positive Oropharyngeal Squamous Cell Carcinoma · Sponsor: PDS Biotechnology Corp.
VERSATILE-002 is a Phase 2, open-label, multicenter study of the efficacy and safety of PDS0101 administered in combination with pembrolizumab in adults with HPV16 and PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Marin Cancer Center | Greenbrae, California, United States | — |
| University of California San Francisco | San Francisco, California, United States | — |
| Mayo Clinic | Jacksonville, Florida, United States | — |
| Cleveland Clinic Florida | Weston, Florida, United States | — |
| University of Kentucky Chandler Medical Center - Markey Cancer Center | Lexington, Kentucky, United States | — |
| University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore, Maryland, United States | — |
| University of Michigan | Ann Arbor, Michigan, United States | — |
| Barbara Ann Karmanos Cancer Institute | Detroit, Michigan, United States | — |
| Mayo Clinic | Rochester, Minnesota, United States | — |
| Atlantic Health | Morristown, New Jersey, United States | — |
| University of North Carolina | Chapel Hill, North Carolina, United States | — |
| Ohio State University | Columbus, Ohio, United States | — |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04260126